Erik D Blake, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3624 River Rd N, Keizer, OR 97303 Phone: 503-561-5976 Fax: 503-561-4912 |
Dr. Xiaoyue Li, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3624 River Rd N, Keizer, OR 97303 Phone: 503-561-5976 |
Mr. James David Hook, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 3624 River Rd N, Keizer, OR 97303 Phone: 503-561-5976 Fax: 503-561-4912 |
Mr. John A French, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3624 River Rd N, Keizer, OR 97303 Phone: 503-561-5976 Fax: 503-561-4912 |
Mr. Dung X Truong, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3624 River Rd N, Keizer, OR 97303 Phone: 503-561-5976 Fax: 503-561-4912 |
Mr. Raymond Brumbaugh, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3624 River Rd N, Keizer, OR 97303 Phone: 503-561-5976 Fax: 503-561-4912 |
News Archive
Cell Therapeutics, Inc. announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled that CTI should be allowed to pursue all of its claims against The Lash Group, sending the case back to the District Court for trial. CTI filed a complaint against The Lash Group, CTI's former third-party reimbursement consultant for CTI's product TRISENOX, in 2007 seeking $22.8 million in damages for expenses already incurred related to the investigation, defense and a settlement of claims by the U.S. government concerning Medicare reimbursement for TRISENOX and other business losses.
HIV/AIDS is "essentially the black death of the 21st century, killing on a massive scale and threatening to cripple economies and topple governments," Fitzhugh Mullan of George Washington University's Department of Health Policy writes in a commentary in the Feb. 21 issue of the Journal of the American Medical Association.
A new center at Indiana University-Purdue University Indianapolis has a tall order to fill - improving the quality of life for billions of people.
Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapies.
› Verified 9 days ago